Compare LYFT Inc (LYFT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Sanofi SA — how do they compare? LYFT Inc trades at $16.2 (market cap $6.11B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 15.6× LYFT Inc's market cap, and Sanofi SA pays a 6.01% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Sanofi SA for 94 Days on average.
| LYFT | SNY | |
|---|---|---|
Market Cap | $6.11B | $95.18B |
Volume | 13,504,560 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $24.57 | $52.34 |
52-Week Low | $12.65 | $39.51 |
Typical Hold Time | 47 Days | 94 Days |
Enterprise Value | $5.57B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.60, down 1.02% with a bullish technical signal despite recent earnings misses. The company shows strong fundamental improvement with revenue growing from $4.1B in 2022 to $6.3B in 2025 and achieving profitability with $2.84B net income. Recent developments include European expansion and a $272.5M legal settlement. Valuation metrics appear attractive with P/E of 2.27 and P/S of 0.93, though EV/EBITDA remains elevated at 33.28.
Lyft presents a mixed outlook with strong cash flow growth and expanding operations balanced against competitive pressures and regulatory risks. The stock trades below analyst consensus target of $18.07, offering potential upside, but faces headwinds from driver classification lawsuits and market saturation concerns. Execution on European expansion and sustained profitability will be key catalysts for further appreciation.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
